These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


810 related items for PubMed ID: 16646003

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents.
    Russo RA, Katsicas MM.
    J Rheumatol; 2009 May; 36(5):1078-82. PubMed ID: 19435972
    [Abstract] [Full Text] [Related]

  • 24. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results.
    van der Heijde D, Klareskog L, Boers M, Landewé R, Codreanu C, Bolosiu HD, Pedersen R, Fatenejad S, TEMPO Investigators.
    Ann Rheum Dis; 2005 Nov; 64(11):1582-7. PubMed ID: 15860509
    [Abstract] [Full Text] [Related]

  • 25. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
    Seitz M, Zwicker M, Villiger PM.
    J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
    [Abstract] [Full Text] [Related]

  • 26. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.
    Kristensen LE, Kapetanovic MC, Gülfe A, Söderlin M, Saxne T, Geborek P.
    Rheumatology (Oxford); 2008 Apr; 47(4):495-9. PubMed ID: 18316338
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA.
    Keystone E, Freundlich B, Schiff M, Li J, Hooper M.
    J Rheumatol; 2009 Mar; 36(3):522-31. PubMed ID: 19228659
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial.
    Pincus T, Strand V, Koch G, Amara I, Crawford B, Wolfe F, Cohen S, Felson D.
    Arthritis Rheum; 2003 Mar; 48(3):625-30. PubMed ID: 12632413
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Symmons DP, Watson KD, Silman AJ, British Society for Rheumatology Biologics Register.
    Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
    [Abstract] [Full Text] [Related]

  • 38. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden.
    Kristensen LE, Saxne T, Geborek P.
    Arthritis Rheum; 2006 Feb; 54(2):600-6. PubMed ID: 16447237
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 41.